Document:

Exhibit 10.24

 

SECURITIES
PURCHASE AGREEMENT

 

SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of __________, 2018, by and between Adial Pharmaceuticals,
Inc., a Delaware corporation, with headquarters located at 1180 Seminole Trail, Charlottesville, Virginia 22901 (the “Company”),
and ____________ with an address at _________________________________ (the “Investor”).

 

WHEREAS:

 

A. The
Company and the Investor are executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”
or “Commission”) under the Securities Act of 1933, as amended (the “1933 Act”).

 

B. The
Investor desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement
an 18% senior secured promissory note of the Company, in the form attached hereto as Exhibit A, in the principal amount
set forth on the signature page of this Agreement (the “Secured Note”). The Company’s obligations under
the Secured Note are secured by the Security Agreement between the Company and the Investor, in the form attached hereto as Exhibit
B (the “Security Agreement”).

 

NOW
THEREFORE, the Company and the Investor hereby agree as follows:

 

1. PURCHASE
AND SALE OF SECURED NOTE.

 

a. Purchase
of Secured Note. On the Closing Date (as defined below), the Company shall issue and sell to the Investor, and the Investor
agrees to purchase from the Company the Secured Note in the principal amount set forth on the signature page of this Agreement
as provided in this Agreement. In addition, within three (3) business days of the consummation by the Company of a debt or equity
financing in the amount of Two Million Dollars ($2,000,000) or more (the “Next Financing”), the Company shall
issue to Investor: (i) a stock purchase warrant to purchase common stock, par value $0.001 per share, of the Company (or other
security issuable if the next Qualified Financing is not a common stock financing) (the “Common Stock”) pursuant
to the terms contained in the form attached as Exhibit C (the “Warrant”). At issuance of the Warrant,
the number of Warrant Shares (as defined in the Warrant) purchasable under the Warrant shall be equal to 400% of the principal
amount of the Secured Note divided by the price per share of Common Stock (or other security issuable if the next Qualified Financing
is not a common stock financing) obtainable under the Next Financing (the “Next Financing Price”) and the Exercise
Price (as defined in the Warrant) shall be equal to Next Financing Price; and (ii) the number of shares of Common Stock
(or other security issuable if the next Qualified Financing is not a common stock financing) equal to the quotient of 400% of
the principal amount of the Secured Note divided by the Next Financing Price (the “Commitment Shares”). This
Agreement, the Secured Note, the Warrant and the Security Agreement are sometimes referred to herein as the “Transaction
Documents”.

 

     

     

    

 

b. Form
of Payment. On the Closing Date, (i) Investor shall pay the purchase price for the Secured Note set forth on the signature
page of the Agreement (the “Purchase Price”) by wire transfer of immediately available funds to the Company,
in accordance with the Company’s written wiring instructions, against delivery by the Company of the Secured Note and the
Security Agreement, and (ii) the Company shall deliver the Secured Note and the Security Agreement, each duly executed on behalf
of the Company, to the Investor, against delivery by the Investor of the Purchase Price.

 

c. Closing
Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below,
the date and time of the issuance and sale of the Secured Note pursuant to this Agreement (the “Closing Date”)
shall be 12:00 noon, Eastern Time on February 22, 2018 or such other mutually agreed upon time. The closing of the transactions
contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed
to by the parties.

 

2. INVESTOR’S
REPRESENTATIONS AND WARRANTIES. Investor represents and warrants to the Company to Investor that:

 

a. Investment
Purpose. As of the date hereof, the Investor is purchasing the Secured Note for its own account and not with a present
view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under
the 1933 Act.

 

b. Accredited
Investor Status. The Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation
D (an “Accredited Investor”).

 

c. Reliance
on Exemptions. The Investor understands that the Secured Note, the Warrant and the shares of Common Stock issuable upon
exercise of the Warrant (such shares of Common Stock being referred to herein as the “Warrant Shares” and, collectively
with the Secured Note and the Warrant, as the “Securities”) are being offered and sold to it in reliance upon
specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions
and the eligibility of the Investor to acquire the Securities.

 

d. Governmental
Review. The Investor understands that no United States federal or state agency or any other government or governmental
agency has passed upon or made any recommendation or endorsement of the Securities.

 

    	 	2	 

     

    

 

e. Transfer
or Re-sale. The Investor understands that (i) the sale or re-sale of the Securities has not been and is not being registered
under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities
are sold pursuant to an effective registration statement under the 1933 Act, (b) the Investor shall have delivered to the Company
an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions
to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration,
which opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined
in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”)) of the Investor who agrees to
sell or otherwise transfer the Securities only in accordance with this Section 2(e) and who is an Accredited Investor, (d) the
Securities are sold pursuant to Rule 144, and the Investor shall have delivered to the Company an opinion of counsel as set forth
in clause (b), or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation
S”), and the Investor shall have delivered to the Company an opinion of counsel that shall be in form, substance and
scope customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred
may be sold or transferred pursuant to an exemption from registration under the 1933 Act, which opinion shall be accepted by the
Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule
and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the person
through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance
with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) other than the piggy-back
registration rights set forth in the Warrant, neither the Company nor any other person is under any obligation to register the
Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder.
Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in
connection with a bona fide margin account or other lending arrangement.

 

f. Legends.
The Investor understands that the Secured Note, the Warrant and, until such time as the Warrant Shares and Commitment Shares have
been registered under the 1933 Act or otherwise may be sold pursuant to Rule 144, the Warrant Shares and Commitment Shares may
bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the
certificates for such Securities):

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED
OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY
SHALL HAVE RECEIVED AN OPINION OF COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS
OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED UNDER SUCH ACT, THE SUBSTANCE OF WHICH OPINION SHALL BE REASONABLY ACCEPTABLE
TO THE COMPANY.”

 

    	 	3	 

     

    

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Securities
upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Securities are registered
for sale under an effective registration statement filed under the 1933 Act, or (b) such holder provides the Company with an opinion
of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public
sale or transfer of such Securities may be made without registration under the 1933 Act, which opinion shall be accepted by the
Company so that the sale or transfer is effected or (c) such holder provides the Company with reasonable assurances that such
Securities can be sold pursuant to Rule 144 or Regulation S and a legal opinion to support such assurances. The Investor agrees
to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance
with applicable prospectus delivery requirements, if any.

 

g. Authorization;
Enforcement. This Agreement and the other Transaction Documents have each been duly and validly authorized by the Investor.
This Agreement and the other Transaction Documents have each been duly executed and delivered on behalf of the Investor, and constitute
valid and binding agreements of the Investor, enforceable against the Investor in accordance with their terms.

 

h. Residency.
The Investor is a resident of the jurisdiction set forth immediately below the Investor’s name on the signature page hereto.

 

i. Restrictions.
The Investor hereby agrees not to sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or
enter into any hedging or similar transaction with the same economic effect as a sale, of any Common Stock (or other securities)
of the Company held by the Investor during the 180-day period following the effective date of the registration statement for the
Company’s initial public offering (including, without limitation, to accommodate regulatory restrictions on (i) the publication
or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) (the “Lock-Up
Period”); provided, that substantially all current holders, including all officers, directors and 5% holders, of the
Company’s voting securities are bound by the same requirement during the Lock-Up Period. The obligations described in this
Section 2(i) shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms
that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may
be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each certificate with a legend as
substantially set forth below with respect to the shares of Common Stock subject to the foregoing restriction until the end of
such 180-day period. To effect the above, the Investor agrees to execute a market stand-off agreement with the underwriters in
the offering in customary form consistent with the provisions of this Section 2(i).

 

j. Non-reliance.
The Investor acknowledges that the Company may not effect a public offering of its securities and the Investor’s decision
to invest in the Company was made independent of and the Investor did not rely upon any public filings of the Company and investor
had the opportunity to conduct its own diligence on the Company, including access to management and the Company’s books
and records.

 

    	 	4	 

     

    

 

3. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Investor that:

 

a. Organization
and Qualification. The Company and each of its Subsidiaries, if any, is a corporation duly organized, validly existing
and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate
and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
and conducted. “Subsidiary” shall mean any corporation or other entity of which at least a majority of the
securities or other ownership interests having ordinary voting power (absolutely or contingently) for the election of directors
or other persons performing similar functions are at the time owned directly or indirectly by the Company and/or any of its other
Subsidiaries.

 

b. Authorization;
Enforcement. The Company has all requisite corporate power and authority to enter into and perform this Agreement and
the other Transaction Documents. This Agreement and the other Transaction Documents have each been duly and validly authorized
by the Company. This Agreement and the other Transaction Documents have each been duly executed and delivered on behalf of the
Company, and constitute valid and binding agreements of the Company, enforceable against the Company in accordance with their
terms.

 

c. Capitalization.
The capitalization of the Company is as set forth on Schedule 3(c) attached hereto. The Company presently has 50,000,000
shares of Common Stock and 5,000,000 shares of preferred stock authorized, of which 4,074,856 shares of common stock are issued
and outstanding. The Company owns all of the outstanding equity interests, if any, of each of its Subsidiaries, free and clear
of any Liens, and there are no outstanding options, warrants or other securities exercisable for or convertible into equity interests
of any Subsidiary of the Company.

 

d. Issuance
of Shares. The Warrant Shares have been duly and validly authorized and reserved for issuance upon exercise of the Warrant
and will, upon issuance, be duly and validly issued, fully paid and non-assessable. The Commitment Shares have been duly and validly
authorized and reserved for issuance upon consummation of a Next Financing and will, upon issuance, be duly and validly issued,
fully paid and non-assessable.

 

e. Acknowledgment
of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance
of the Warrant Shares and Commitment Shares.

 

f. Bad
Actor Representation. None of the Company, any of its Subsidiaries, predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”
and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications
described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person
is subject to a Disqualification Event.

 

    	 	5	 

     

    

 

g. Litigation.
There is no action, suit, proceeding, or investigation (including without limitation any suit, proceeding, or investigation
involving the prior employment of any of employees of the Company or any Subsidiary, their use in connection with the Company’s
business of any information or techniques allegedly proprietary to any of their former employers, or their obligations under any
agreements with prior employers) pending or, to the best of the Company’s knowledge, currently threatened before any court,
administrative agency, or other governmental body against the Company, any Subsidiary or any of their respective assets or properties.
Neither the Company nor any Subsidiary is a party or subject to, and none of their respective assets is bound by, the provisions
of any order, writ, injunction, judgment, or decree of any court or government agency or instrumentality. There is no action,
suit, or proceeding by the Company or any Subsidiary currently pending or that the Company or any Subsidiary intends to initiate.

 

h. Disclosure.
The Company has fully provided the Investor with all the information that the Investor has requested for deciding whether
to purchase the Securities and all material information that is reasonably necessary to enable a reasonable Investor to make such
decision. Neither this Agreement or the other Transaction Documents, nor any other agreements, statements or certificates made
or delivered to Investor in connection herewith or therewith contains any untrue statement of a material fact or, when taken together,
omits to state a material fact necessary to make the statements herein or therein, in light of the circumstances under which they
were made, not misleading.

 

i. Shell
Company Status. During the previous twelve (12) months, the Company has not been a shell as such term is defined in Rule
144(i) under the 1933 Act.

 

j. Financial
Statements. The consolidated financial statements of the Company and its Subsidiaries annexed hereto (the “Financial
Statements”) comply as to form in all material respects with applicable accounting requirements and the published rules
and regulations of the Commission or other applicable rules and regulations with respect thereto. The Financial Statements have
been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on
a consistent basis during the periods involved (except (i) as may be otherwise indicated in the Financial Statements or the Notes
thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnote or may be condensed or
summary statements), and fairly present in all material respects the consolidated financial position of the Company and its Subsidiaries
as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited
statements, to normal year-end audit adjustments, which will not be material).

 

k. No
Material Adverse Effect. Since December 31, 2017, neither the Company nor any Subsidiary has experienced or suffered any
Material Adverse Effect. For the purposes of this Agreement, “Material Adverse Effect” means any of (i) a material
and adverse effect on the legality, validity or enforceability of this Agreement or the other Transaction Documents; (ii) a material
adverse effect on the business, operations, properties, or financial condition of the Company, its Subsidiaries, individually,
or in the aggregate and/or any condition, circumstance, or situation that would prohibit or otherwise materially interfere with
the ability of the Company or any Subsidiary to perform any of their obligations under this Agreement or the other Transaction
Documents in any material respect; or (iii) an adverse impairment to the ability of the Company or any Subsidiary to perform on
a timely basis their obligations under this Agreement or the other Transaction Documents.

 

    	 	6	 

     

    

 

l. No
Undisclosed Liabilities. Except as shown on Schedule 3(l), neither the Company nor any Subsidiary has any liabilities,
obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise)
not reflected in the Financial Statements, other than those incurred in the ordinary course of the Company’s and any Subsidiary’s
respective businesses since the date of the Financial Statements.

 

m. No
Undisclosed Events or Circumstances. To the Company’s knowledge, no event or circumstance has occurred or exists
with respect to the Company or any Subsidiary or their respective businesses, properties, operations or financial condition, which,
under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so
publicly announced or disclosed.

 

n. Indebtedness.
Other than as set forth on Schedule 3(n), the Financial Statements set forth all outstanding secured and unsecured Indebtedness
of the Company or any Subsidiary. For the purposes of this Agreement, “Indebtedness” shall mean (i) any liabilities
for borrowed money or amounts owed (other than trade accounts payable incurred in the ordinary course of business); (ii) all guaranties,
endorsements and other contingent obligations in respect of Indebtedness of others, whether or not the same should be reflected
in the consolidated balance sheet of the Company and its Subsidiaries (or the notes thereto), except guaranties by endorsement
of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (iii) the
present value of any lease payments due under leases required to be capitalized in accordance with GAAP. Neither the Company nor
any Subsidiary is in default with respect to any Indebtedness and no event has occurred that could reasonably be expected to result
in any such Indebtedness.

 

o. Title
to Assets. The Company and its Subsidiaries each have good and marketable title in fee simple to all real property owned
by it and good and marketable title in all personal property owned by it that is material to the respective businesses of the
Company and its Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and
its Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made
therefore in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties (liens referenced in
subsection (i) and (ii) above are collectively referred to as "Permitted Liens"). Any real property and facilities
held under lease by the Company or any Subsidiary are held by it under valid, subsisting and enforceable leases with which the
Company or such Subsidiary is in compliance.

 

    	 	7	 

     

    

 

p. Actions
Pending. There is no action, suit, claim, investigation, arbitration, alternate dispute resolution proceeding or any other
proceeding pending or, to the knowledge of the Company, threatened against or involving the Company or any Subsidiary which questions
the validity of this Agreement or any of the other Transaction Documents or the transactions contemplated hereby or thereby or
any action taken or to be taken pursuant hereto or thereto. There are no outstanding orders, judgments, injunctions, awards or
decrees of any court, arbitrator or governmental or regulatory body pending or, to the Company’s knowledge, threatened against
the Company or any Subsidiary or any of their respective executive officers or directors in their capacities as such.

 

q. Compliance
with Law. The Company and its Subsidiaries have all material franchises, permits, licenses, consents and other governmental
or regulatory authorizations and approvals (collectively, “Permits”) necessary for the conduct of their respective
business as now being conducted by it in compliance with applicable law and neither the Company or the applicable Subsidiary is
in violation or breach of any such Permit.

 

r. Compliance.
Neither the Company nor any Subsidiary: (i) is in default under or in material violation of (and no event has occurred that has
not been waived that, with notice or lapse of time or both, would result in a default or material violation by the Company or
any Subsidiary), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in
material violation of, any indenture, or loan or credit agreement to which it is a party or by which it or any of its properties
is bound (whether or not such default or violation has been waived); (ii) is in material violation of any judgment, decree or
order of any court, arbitrator or other governmental authority; or (iii) is or has been in material violation of any statute,
rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local
laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and
labor matters.

 

s. Consents
and Approvals. Neither the Company nor any Subsidiary is required: (a) under any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound; or (b) under federal,
state, local or foreign law, rule or regulation, to obtain any consent, authorization or order of, or make any filing or registration
with, any counterparty to any such indenture, loan or credit agreement or other agreement or instrument, or any court or governmental
agency, in order for it to execute, deliver or perform any of its obligations under this Agreement and the other Transaction Documents,
or issue and sell the Secured Note, the Warrant, the Warrant Shares or the Commitment Shares in accordance with the terms hereof
or thereof (other than (x) any consent, authorization or order that has been obtained as of the date hereof, (y) any filing or
registration that has been made as of the date hereof or (z) any filings which may be required to be made by the Company with
the Commission or state securities administrators subsequent to the Closing). The Company and its Subsidiaries have obtained all
approvals of their respective board of directors and stockholders required in connection with their execution, delivery and performance
of this Agreement and the other Transaction Documents and consummation of the transactions contemplated herein and therein, including
the issuance and sale of the Secured Note, the Warrant, the Warrant Shares or the Commitment Shares.

 

    	 	8	 

     

    

 

t. No
Conflicts. The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company
and its Subsidiaries and the consummation by the Company and its Subsidiaries of the transactions contemplated herein and therein
do not and will not (i) materially violate any provision of their respective organizational documents, (ii) materially conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture,
note, bond, license, lease agreement, instrument or obligation to which the Company or any Subsidiary is a party or by which it
or its properties or assets are bound, (iii) create or impose a lien, mortgage, security interest, pledge, charge or encumbrance
(collectively, “Lien”) of any nature on any property of the Company or any Subsidiary under any agreement or
any commitment to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound or by which
any of its respective properties or assets are bound, or (iv) result in a material violation of any federal, state, local or foreign
statute, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable
to the Company or any Subsidiary or by which any property or asset of the Company, or any Subsidiary are bound or affected.

 

u. Taxes.
Each of the Company and its Subsidiaries, to the extent applicable, has accurately prepared and filed all federal, state and other
tax returns required by law to be filed by it in compliance with applicable law, has paid or made provisions for the payment of
all taxes shown to be due (other than payments being contested in good faith for which adequate provisions have been and are reflected
in the consolidated financial statements of the Company and its Subsidiaries). None of the federal income tax returns of the Company
or any Subsidiary have been audited by the Internal Revenue Service. The Company has no knowledge of any additional assessments,
adjustments or contingent tax liability (whether federal, state or foreign) of any nature whatsoever, whether pending or threatened
against the Company or any Subsidiary for any period, nor of any basis for any such assessment, adjustment or contingency.

 

v. Intellectual
Property. Each of the Company and its Subsidiaries, owns or has the lawful right to use all patents, trademarks, domain
names (whether or not registered) and any patentable improvements or copyrightable derivative works thereof, websites and intellectual
property rights relating thereto, service marks, trade names, copyrights, licenses and authorizations, if any, and all rights
with respect to the foregoing (collectively, “Intellectual Property”), if any, which are necessary for the
conduct of their respective business as now conducted, each of which is valid, subsisting and in full force and effect. To the
knowledge of the Company, neither the Company nor any Subsidiary is infringing upon any Intellectual Property rights of any other
person or entity and, to the Company’s knowledge, no other person or entity is infringing upon any Intellectual Property
rights of the Company or any Subsidiary.

 

w. Books
and Records Internal Accounting Controls. The books and records of the Company and its Subsidiaries accurately reflect
in all material respects the information relating to the business of the Company and its Subsidiaries, the location and collection
of their assets, and the nature of all transactions giving rise to the obligations or accounts receivable of the Company and its
Subsidiaries. The Company and its Subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s general or specific authorization and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate actions are taken
with respect to any differences.

 

    	 	9	 

     

    

 

x. Material
Agreements. Any and all written or oral contracts, instruments, agreements, commitments, obligations, plans or arrangements,
the Company or any of its Subsidiaries is a party to, that a copy of which would be required to be filed with the Commission as
an exhibit to a registration statement (collectively, the “Material Agreements”), if the Company or any Subsidiary
were registering securities under the 1933 Act, has previously been publicly filed with the Commission. Each of the Company and
its Subsidiaries has in all material respects performed all the obligations required to be performed by them to date under the
Material Agreements, and neither has received any notice of material breach or default, and the Company and its Subsidiaries are
not in material breach or default, under any Material Agreement and neither, to the Company’s knowledge, is any other party
to any Material Agreement in material breach of, or default under, any Material Agreement.

 

y. Transactions
with Affiliates. Except as disclosed in the Company’s filings with the Commission and herein, there are no loans,
leases, agreements, contracts, royalty agreements, management contracts or arrangements or other transactions between (a) the
Company or any Subsidiary on the one hand, and (b) on the other hand, any officer, employee, consultant or director of the Company
or any Subsidiary, or any person owning more than 10% capital stock of the Company or any Subsidiary, or any member of the immediate
family of such officer, employee, consultant, director or stockholder or any corporation or other entity controlled by such officer,
employee, consultant, director or stockholder, or a member of the immediate family of such officer, employee, consultant, director
or stockholder.

 

z. Brokers.
The Company has taken no action which would give rise to any claim by any person or entity for brokerage commissions, transaction
fees or similar payments relating to this Agreement or the transactions contemplated hereby.

 

aa. Private
Placement and Solicitation. Assuming the accuracy of the Investor’s representations and warranties set forth
in Section 2, no registration under the 1933 Act is required for the offer and sale of the Securities by the Company to the
Investor as contemplated hereby. Based in part on the accuracy of the representations of the Investor in Section 2, and
subject to timely applicable Form D filings pursuant to Regulation D of the 1933 Act with the Commission and pursuant to
applicable state securities laws, the offer, sale and issuance of the Securities to be issued pursuant to and in conformity
with the terms of this Agreement, will be issued in compliance with all applicable federal and state securities laws. Neither
the Company nor any of its Subsidiaries or other affiliates, nor any person acting on its or their behalf, has engaged in any
form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act) in connection
with the offer or sale of any of the Secured Note, Warrant or Warrant Shares.

 

bb. Employees.
Neither the Company nor any Subsidiary has any collective bargaining arrangements covering any of its employees. Since
December 31, 2017, no officer, consultant or key employee of the Company or any Subsidiary has terminated or, to the
knowledge of the Company, has any present intention of terminating, his or her employment or engagement with the Company or
any Subsidiary.

 

    	 	10	 

     

    

 

4. COVENANTS.
While the Note is outstanding, the Company make the following covenants.

 

a. Best
Efforts. The parties shall use their best efforts to satisfy timely each of the conditions described in Section 6 and
7 of this Agreement.

 

b. Blue
Sky Laws. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine
is necessary to qualify the Securities for sale to the Investor at the applicable closing pursuant to this Agreement under applicable
securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such qualification),
and shall provide evidence of any such action so taken to the Investor on or prior to the Closing Date.

 

c. Use
of Proceeds. The Company shall use the proceeds from the sale of the Secured Note solely for general working capital purposes
in the ordinary course of business, consistent with past practice, and shall not, directly or indirectly, use any of such proceeds
for: (i) any distribution or dividend to any shareholder of the Company, (ii) payment of any bonus or other compensation to any
officer, director or other employee of the Company or any Subsidiary (other than payment of salaries to employees in the ordinary
course of business consistent with past practice), or (iii) the repayment of any Indebtedness of the Company or any Subsidiary.

 

d. Securities
Compliance. The Company shall notify the Commission in accordance with its rules and regulations, of the transactions
contemplated by this Agreement and the Transaction Documents, including filing a Form D with respect to the Securities, as required
under Regulation D and applicable “blue sky” laws if such Securities are offered pursuant to Rule 506 of Regulation
D and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and regulation,
for the legal and valid issuance of the Secured Note, the Warrant, the Warrant Shares and the Commitment Shares to the Investor
or subsequent holders.

 

e. Liquidation.
Subject to the terms of the other Transaction Documents, the Company covenants that it will take such further action as the Investor
may reasonably request, all to the extent required from time to time to enable the Investor to sell the Securities without registration
under the 1933 Act within the limitation of the exemptions provided by Rule 144 promulgated under the 1933 Act, as amended.

 

f. Keeping
of Records and Books of Account. The Company shall keep and cause each Subsidiary to keep adequate records and books of
account, in which complete entries will be made in accordance with GAAP consistently applied, reflecting all financial transactions
of the Company and its Subsidiaries, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence,
amortization, taxes, bad debts and other purposes in connection with its business shall be made.

 

g. Amendments.
The Company will not and will not permit any Subsidiary to amend, modify or waive any term
or provision of its organizational documents, or any shareholders agreement, other than amendments, modifications and waivers
that are not materially adverse in any respect to the Investor and of which the Investor have received at least five (5) Business
Days’ prior written notice.

 

    	 	11	 

     

    

 

h. Other
Agreements. The Company shall not and shall cause its Subsidiaries to not, enter into any agreement the terms of which
would restrict or impair the ability of the Company or any Subsidiary to perform their obligations under this Agreement and the
other Transaction Documents.

 

i. Disposition
of Assets. While the Secured Note or any principal amount, interest, fees or other amounts due thereunder remains outstanding
and unpaid, neither the Company nor any of its Subsidiaries shall sell, transfer or otherwise dispose of any of their material
properties, assets and rights including, without limitation, its software and Intellectual Property, to any person except for
(i) sales or non-exclusive licenses to customers in the ordinary course of business, (ii) sales or transfers between the Company
and the Subsidiaries, (iii) disposition of obsolete or worn out equipment, or (iv) otherwise with the prior written consent of
the Investor.

 

j. Most
Favored Nation. While the Secured Note or any principal amount, interest or fees or expenses due thereunder remain outstanding
and unpaid, the Company shall not enter into any public or private offering of its securities (including securities convertible
into shares of Common Stock) with any individual or entity (an “Other Investor”) that has the effect of establishing
rights or otherwise benefiting such Other Investor in a manner more favorable in any material respect to such Other Investor than
the rights and benefits established in favor of the Investor by this Agreement or the Secured Note unless, in any such case, the
Investor has been provided with written notice (the “Company Notice”) and no less than 10 days to exercise
the right, but not the obligation, to exchange its rights and obligations hereunder (i.e. to the Securities) for the rights and
obligations established with the Other Investor. In order to exercise such right, Investor shall send the Company a written notice
of its exercise (the “Investor Notice”). If the Investor Notice is not received by the Company within ten (10)
days of Investor’s receipt of the Company Notice, the rights under this Section shall terminate with respect to such offering
of the Company’s securities. Notwithstanding the foregoing, this Section 4(k) shall not include: (i) securities issued in
the Company’s initial public offering (including any warrants issued to the underwriters); (ii) the issuance and/or sale
of securities by the Company in connection with a business acquisition, joint ventures or partnerships; (iii) the issuance by
the Company of shares of common stock upon the exercise of a stock option or warrant or the conversion of a security outstanding
on the date of this Note; and (iv) the issuance of securities by the Company as compensation.

 

k. Sarbanes-Oxley
Act. Except as disclosed in the Company’s filings with the Commission, the Company shall be in compliance
with the applicable provisions of the Sarbanes-Oxley Act of 2002, and the rules and regulations promulgated thereunder, as required
under such Act.

 

l. No
Integrated Offerings. The Company shall not make any offers or sales of any security (other than the securities being
offered or sold hereunder) under circumstances that would require registration of the Securities being offered or sold hereunder
under the 1933 Act.

 

    	 	12	 

     

    

 

m. Legal
Counsel Opinions. Upon the request of the Investor from time to time, the Company shall be responsible (at its cost) for
promptly supplying to the Company’s transfer agent and the Investor a customary legal opinion letter of its counsel (the
“Legal Counsel Opinion”) to the effect that the resale of the Warrant Shares or Commitment Shares by the Investor
or its affiliates, successors and assigns is exempt from the registration requirements of the 1933 Act pursuant to Rule 144 (provided
the requirements of Rule 144 are satisfied and provided the Warrant Shares or Commitment Shares are not then registered under
the 1933 Act for resale pursuant to an effective registration statement). Should the Company’s legal counsel fail for any
reason to issue the Legal Counsel Opinion, the Investor may (at the Company’s cost) secure another legal counsel to issue
the Legal Counsel Opinion, and the Company will instruct its transfer agent to accept such opinion. The Company hereby agrees
that it may never take the position that it is a “shell company” in connection with its obligations under this Agreement
or otherwise.

 

n. Variable
Rate Transactions. While the Secured Note or any principal amount, interest or fees or expenses due thereunder remain
outstanding and unpaid, the Company shall be prohibited from effecting or entering into an agreement involving a Variable Rate
Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares
of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies
with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or
equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after
the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or (ii) enters into any agreement, including, but not
limited to, an equity line of credit, whereby the Company may issue securities at a future determined price. The Investor shall
be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to
any right to collect damages.

 

5. INDEMNITY.

 

a. General
Indemnity. The Company agrees to indemnify and hold harmless the Investor (and its directors, officers, affiliates, managers,
partners, members, shareholders, affiliates, agents, successors and assigns) (collectively, the “Investor Indemnified
Parties”) from and against any and all losses, liabilities, deficiencies, costs, damages and expenses (including, without
limitation, reasonable attorneys’ fees, charges and disbursements) incurred by the Investor Indemnified Parties as a result
of any breach of the representations, warranties or covenants made by the Company herein or in any other Transaction Document.
The Investor agrees to indemnify and hold harmless the Company and its directors, officers, affiliates, agents, successors and
assigns (the “Company Indemnified Parties”) from and against any and all losses, liabilities, deficiencies,
costs, damages and expenses (including, without limitation, reasonable attorneys’ fees, charges and disbursements) incurred
by the Company Indemnified Parties as a result of any breach of the representations, warranties or covenants made by the Investor
herein or in any other Transaction Document. The maximum aggregate liability of the Investor pursuant to its indemnification obligations
under this Section 5 shall not exceed the Purchase Price paid by the Investor hereunder. In no event shall any “Indemnified
Party” (as defined below) be entitled to recover consequential or punitive damages resulting from a breach or violation
of this Agreement.

 

    	 	13	 

     

    

 

b. Indemnification
Procedure. Any Investor Indemnified Party or Company Indemnified Party entitled to indemnification under this Section
5 (an “Indemnified Party”) will give written notice to the indemnifying party of any matters giving rise to
a claim for indemnification; provided, that the failure of any party entitled to indemnification hereunder to give notice
as provided herein shall not relieve the indemnifying party of its obligations under this Section 5 except to the extent that
the indemnifying party is actually prejudiced by such failure to give notice. In case any action, proceeding or claim is brought
against an Indemnified Party in respect of which indemnification is sought hereunder, the indemnifying party shall be entitled
to participate in and, unless in the reasonable judgment of the Indemnified Party a conflict of interest between it and the indemnifying
party may exist with respect of such action, proceeding or claim, to assume the defense thereof with counsel reasonably satisfactory
to the Indemnified Party. In the event that the indemnifying party advises an Indemnified Party that it will contest such a claim
for indemnification hereunder, or fails, within thirty (30) days of receipt of any indemnification notice to notify, in writing,
such person of its election to defend, settle or compromise, at its sole cost and expense, any action, proceeding or claim (or
discontinues its defense at any time after it commences such defense), then the Indemnified Party may, at its option, defend,
settle or otherwise compromise or pay such action or claim. In any event, unless and until the indemnifying party elects in writing
to assume and does so assume the defense of any such claim, proceeding or action, the Indemnified Party’s costs and expenses
arising out of the defense, settlement or compromise of any such action, claim or proceeding shall be losses subject to indemnification
hereunder. The Indemnified Party shall cooperate fully with the indemnifying party in connection with any negotiation or defense
of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available
to the Indemnified Party which relates to such action or claim. The indemnifying party shall keep the Indemnified Party fully
apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. If the indemnifying
party elects to defend any such action or claim, then the Indemnified Party shall be entitled to participate in such defense with
counsel of its choice at its sole cost and expense. The indemnifying party shall not be liable for any settlement of any action,
claim or proceeding effected without its prior written consent, provided, however, that the indemnifying party shall
be liable for any settlement if the indemnifying party is advised of the settlement but fails to respond to the settlement within
thirty (30) days of receipt of such notification. Notwithstanding anything in this Section 5 to the contrary, the indemnifying
party shall not, without the Indemnified Party’s prior written consent, settle or compromise any claim or consent to entry
of any judgment in respect thereof which imposes any future obligation on the Indemnified Party or which does not include, as
an unconditional term thereof, the giving by the claimant or the plaintiff to the Indemnified Party of a release from all liability
in respect of such claim. The indemnity agreements contained herein shall be in addition to (a) any cause of action or similar
rights of the Indemnified Party against the indemnifying party or others, and (b) any liabilities the indemnifying party may be
subject to pursuant to the law.

 

6. CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL. The obligation of the Company hereunder to issue and sell the Secured Note
to the Investor at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions,
provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole
discretion:

 

a. The
Investor shall have executed this Agreement and the other Transaction Documents and delivered the same to the Company.

 

    	 	14	 

     

    

 

b. The
Investor shall have delivered the Purchase Price in accordance with Section 1(b) above.

 

c. The
representations and warranties of the Investor shall have been true and correct when made and be true and correct in all material
respects as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date), and the Investor shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to the Closing Date.

 

d. No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement.

 

7. CONDITIONS
TO INVESTOR’S OBLIGATION TO PURCHASE. The obligation of the Investor hereunder to purchase the Secured Note at the
Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these
conditions are for the Investor’s sole benefit and may be waived by the Investor at any time in its sole discretion:

 

a. The
Company shall have executed this Agreement and the Secured Note and delivered the same to the Investor.

 

b. The
representations and warranties of the Company shall have been true and correct when made and be true and correct in all material
respects as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific
date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.

 

c. No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement or the other Transaction Documents.

 

d. No
event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company.

 

    	 	15	 

     

    

 

8. GOVERNING
LAW; MISCELLANEOUS.

 

a. Governing
Law. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK
APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICT OF
LAWS. THE PARTIES HERETO HEREBY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN MANHATTAN,
NEW YORK WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS AGREEMENT, THE AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THEREBY. BOTH PARTIES IRREVOCABLY WAIVE THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH
SUIT OR PROCEEDING. BOTH PARTIES FURTHER AGREE THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS MAIL SHALL BE DEEMED
IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH SUIT OR PROCEEDING. NOTHING HEREIN SHALL AFFECT EITHER
PARTY’S RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. BOTH PARTIES AGREE THAT A FINAL NON-APPEALABLE JUDGMENT
IN ANY SUCH SUIT OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT OR IN ANY
OTHER LAWFUL MANNER. THE PARTY WHICH DOES NOT PREVAIL IN ANY DISPUTE ARISING UNDER THIS AGREEMENT SHALL BE RESPONSIBLE FOR ALL
FEES AND EXPENSES, INCLUDING ATTORNEYS’ FEES, INCURRED BY THE PREVAILING PARTY IN CONNECTION WITH SUCH DISPUTE.

 

b. Counterparts;
Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed
by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party
hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

c. Headings.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation
of, this Agreement.

 

d. Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

e. Entire
Agreement; Amendments. This Agreement and the other Transaction Documents contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company
nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this
Agreement may be waived or amended other than by an instrument in writing signed by the party to be charged with enforcement of
such waiver or amendment.

 

    	 	16	 

     

    

 

f. Notices.
Any notices required or permitted to be given under the terms of this Agreement shall be sent by certified or registered mail
(return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile
and shall be effective five (5) days after being placed in the mail, if mailed by regular United States mail, or upon receipt,
if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, in each case addressed
to a party. The addresses for such communications shall be:

 

	If to
    the Company, to:	ADial
    Pharmaceuticals, LLC
	 	1180 Seminole Trail
	 	Charlottesville,
    Virginia 22901
	 	Attention: William
    B. Stilley
	 	Telephone:
    (212) 217-6725
	 	Facsimile:
(434) 422-9797

	 	 
	With
    a copy to:	Gracin
& Marlow, LLP

        The
Chrysler Building

        405
Lexington Avenue, 26th Floor

        New
York, New York 10174

        Telephone
No.: (212) 907-6457

        Facsimile
No.: (212) 208-4657

        Attention:
Leslie Marlow, Esq.

E-mail: lmarlow@gracinmarlow.com

 

If
to the Investor, to the address set forth on the signature page. Each party shall provide notice to the other party of any change
in address.

 

g. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor the Investor shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other. Notwithstanding the foregoing, subject to Section 2(e), the Investor may assign its rights hereunder to
any person that purchases Securities in a private transaction from the Investor or to any of its “affiliates,” as
that term is defined under the 1934 Act, without the consent of the Company.

 

h. Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    	 	17	 

     

    

 

IN
WITNESS WHEREOF, the Investor and the Company have caused this Agreement to be duly executed as of the date first above written.

 

COMPANY:

 

ADIAL
PHARMACEUTICALS, INC.

 

	By: 	 	 
	Name: 	William B. Stilley	 
	Title: 	Chief Executive Officer	 
	 	 	 
	INVESTOR:	 
	 	 	 
	By: 	 	 
	Name: 	 	 
	Title: 	 	 
	 	 	 
	Address:	 

 

Principal
Amount of Note being Purchased: $ _________________

 

    	 	18	 

     

    

 

SCHEDULES
TO SECURITIES PURCHASE AGREEMENT

 

Schedule
3(c) – Capitalization

 

 

Schedule
3(l) – Undisclosed Liabilities

 

In
November 2017, we issued subordinated notes in the aggregate principal amount of $115,000 to certain of our directors and a consultant
and received proceeds of $100,000 from said loans. The notes bear interest of 2% annually and the holders of the notes have the
right to require repayment of 108.65% of the outstanding principal amount plus interest upon the Company receiving proceeds of
$250,000 or more from the sale of its equity (or equivalent securities) or the issuance of debt. The note matures on May 20, 2018,
and upon maturity $125,000 will be paid in full satisfaction of the principal and outstanding interest.

 

On
January 29, 2018, the board of directors of the Company authorized engagement of Medical Translation Company, a firm controlled
by Bankole Johnson, to translate a patent for filing in multiple jurisdictions in Europe. The total cost is approximately $67,000
paid on a payment schedule plus the issuance of approximately 22,435 common shares of the Company’s stock. Additionally,
on January 29, 2018, the Company agreed that if it could not reimburse William Stilley for his payment of expenses on the Company’s
behalf, that he could be paid on a similar payment scheduled if a number of shares of common stock similar to that issued to Medical
Translation Company were issued to him, with such number be proportional to the amount unreimbursed.

 

Schedule
3(n) – Indebtedness

 

On
February 22, 2018, the Company entered into a Settlement Agreement with FirstFire Global Opportunity Fund, LLC (“FirstFire”),
a Delaware limited liability company, with its address at 1040 First Avenue, Suite 190, New York, NY 10022, pursuant to which
the parties general releases to each other; upon the next financing of the Company, FirstFire is to be issued a common stock purchase
warrant to acquire shares of common stock exercisable for a period of two years to purchase stock having an underlying value of
$325,000 based on the price and securities of the Company’s next financing and with an exercise price equal to the price
of the Company’s next financing and FirstFire is to be issued shares of the Company with a value equal to $50,000 based
on the price and securities of the Company’s next financing; and FirstFire is to be paid $100,000 upon the occurrence of
the next financing or upon repayment of the Secured Note.

 

Any
other financing agreements of like tenor to the Transaction Documents issued pursuant to the financing of which this Agreement
is part.

 

    	 	19	 

     

    

 

Exhibit
A

 

Form
of Senior Secured Promissory Note

 

Reference
is made to Exhibit 4.18 to the Registration Statement on Form S-1 (File Number 333-220368) of the Company, which is incorporated
by reference.

 

    	 	20	 

     

    

 

Exhibit
B

 

Form
of Security Agreement

 

Reference
is made to Exhibit 4.19 to the Registration Statement on Form S-1 (File Number 333-220368) of the Company, which is incorporated
by reference.

 

    	 	21	 

     

    

 

Exhibit
C

 

Form
of Common Stock Warrant (Insider and Non-Insider)

 

Reference
is made to Exhibit 4.20(a) and 4.20(b) to the Registration Statement on Form S-1 (File Number 333-220368) of the Company, which
is incorporated by reference.

 

 

22Exhibit
10.25

 

BACKSTOP
COMMITMENT AGREEMENT 

 

BACKSTOP
COMMITMENT AGREEMENT (this “Agreement”), dated as of February 22, 2018, by and among Adial Pharmaceuticals, Inc.,
a company organized under the laws of the state of Delaware, (the “Company”) and MVA 151 Investors LLC, a Virginia
limited liability company, (the “Backstop Investor”; and together with the Company, the “Parties” and
each a “Party”).

 

RECITALS

 

WHEREAS,
the Company is currently raising bridge financing in the amount up to $550,000 (the “Bridge Financing”) whereby investors
(each an “Investor” and collectively, the “Investors”) will be issued: (i) upon funding of the bridge
financing a note in the principal amount of their cash investment (a “Bridge Note”): (ii) upon consummation of the
next financing of $2,000,000 or more (a “Qualified Financing”) a warrant exercisable for a number of shares of common
stock equal to 400% of the Investor’s cash investment divided by the per share price of the common stock issued (or other
security issuable if the next Qualified Financing is not a common stock financing) in the Company’s next Qualified Financing
(a “Bridge Warrant”); and (iii) upon consummation of the next Qualified Financing such number of shares of the Company’s
common stock as shall equal 400% of the Investor’s cash investment divided by the per share price of the common stock issued
(or other security issuable if the next Qualified Financing is not a common stock financing) in the Company’s next Qualified
Financing (“Bridge Shares”);

 

WHEREAS,
in order to facilitate the Bridge Financing, the Backstop Investor has agreed to invest in the Bridge Financing by 5:00 p.m. EST
on March 1, 2018 (the “Effective Time”), the difference between $400,000 and the amount of funds that the Company
has received from investors in the Bridge Financing at such time (the “Backstop Commitment”) with it agreed between
the Parties that such Backstop Commitment creates a total potential liability for the Backstop Investor equal to the $400,000
less any amounts invested by investors other than the Backstop Investor prior to noon on February 22, 2018 but not including any
funds invested as a result of the payment or settlement of any of the promissory notes issued by the Company on November 21, 2017,
which amount is hereby agreed by the Parties to be $242,000 (the “Backstop Amount”); and

 

WHEREAS,
in consideration of the Backstop Investor’s agreement to make the investment in the foregoing recital, the Company agrees
to issue to the Backstop Investor, in addition to the Bridge Note, Bridge Warrant and Bridge Shares to be received by the Backstop
Investor in the Bridge Financing or as a result of the Bridge Financing (i) upon consummation of the next Qualified Financing
a warrant exercisable for a number of shares of common stock equal to 150% of the Backstop Amount divided by the per share price
of the common stock issued (or other security issuable if the next Qualified Financing is not a common stock financing) in the
Company’s next Qualified Financing under terms substantially similar to the Bridge Warrant (the “Backstop Warrant”);
and (ii) upon consummation of the next Qualified Financing such number of shares of the Company’s common stock as shall
equal 50% of the Backstop Amount divided by the per share price of the common stock issued (or other security issuable if the
next Qualified Financing is not a common stock financing) in the Company’s next Qualified Financing under terms substantially
similar to the Bridge Shares (the “Backstop Shares”).

 

    	 	1	 

     

    

 

NOW,
THEREFORE, in consideration of the premises and of the mutual agreements contained herein, and for other good and valuable
consideration the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties
hereto agree as follows:

 

1.
 BRIDGE FINANCING; BACKSTOP; COMMITMENT FEE. 

 

1.1.  Bridge Financing.

 

(a)
The Company shall commence the Bridge Financing on the date hereof.

 

(b)
The Company hereby agrees and undertakes to give, or to cause to be given, to the Backstop Investor as soon as reasonably practicable written
notification via email setting forth the aggregate amount of cash received in the Bridge Financing.

 

1.2. Backstop. On the terms and subject to the conditions contained herein, the Backstop
Investor hereby agrees to invest the Backstop Commitment in the Bridge Financing no later than the Effective Time, and the Company
hereby agrees to sell and issue to the Backstop Investor, a Bridge Note in the amount of the Backstop Commitment and, upon consummation
of a Qualified Financing, a Bridge Warrant and the Bridge Shares under the terms of the Bridge Financing.

 

1.3. Backstop Fee. In consideration of the Backstop Commitment and after receipt of
the Backstop Commitment funds, the Company agrees to issue to the Backstop Investor upon a Qualified Financing, in addition to
the Bridge Note, Bridge Warrant and Bridge Shares to be received by the Backstop Investor in the Bridge Financing or as a result
of the Bridge Financing, (i) the Backstop Warrant, and (ii) the Backstop Shares.

 

2. LOCK
UP AGREEMENT.

 

2.1 Lock-up
Agreement. Backstop Investor hereby agrees not to sell or otherwise transfer, make any short sale of, grant any option
for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any securities
(or other securities) of the Company held by Backstop Investor during the 180-day period following the effective date of the registration
statement for the Company’s initial public offering (including, without limitation, to accommodate regulatory restrictions
on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but
not limited to, the restrictions contained in FINRA Rule 2241 or NYSE Rule 472(f)(4), or any successor provisions or amendments
thereto) (the “Lock-Up Period”); provided, that substantially all officers, directors and 5% holders, of the Company’s
voting securities are bound by the same or a substantially similar requirement during the Lock-Up Period. The obligations described
in this Section shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar
forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that
may be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each certificate with a legend
as substantially set forth below with respect to the shares of Common Stock subject to the foregoing restriction until the end
of such 180-day period. To effect the above, Backstop Investor agrees to execute a market stand-off agreement with the underwriters
in the offering in customary form consistent with the provisions of this Section 2.

 

3. BACKSTOP
INVESTOR’S REPRESENTATIONS AND WARRANTIES. Backstop Investor represents and warrants to the Company that:

 

3.1 
Investment Purpose. As of the date hereof, the Backstop Investor is purchasing the Backstop Warrant and Backstop
Shares (collectively, the “Securities”) for its own account and not with a present view towards the public sale or
distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

 

    	 	2	 

     

    

 

3.2 
Accredited Investor Status. The Backstop Investor is an “accredited investor” as that term is defined
in Rule 501(a) of Regulation D (an “Accredited Investor”).

 

3.3 
Reliance on Exemptions. The Backstop Investor understands that the Securities are being offered and sold to it in
reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that
the Company is relying upon the truth and accuracy of, and the Backstop Investor’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Backstop Investor set forth herein in order to determine the
availability of such exemptions and the eligibility of the Investor to acquire the Securities.

 

3.4 
Governmental Review. The Backstop Investor understands that no United States federal or state agency or any other
government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

 

3.5 
Transfer or Re-sale. The Backstop Investor understands that (i) the sale or re-sale of the Securities has not been
and is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred
unless (a) the Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) the Backstop Investor
shall have delivered to the Company an opinion of counsel that shall be in form, substance and scope customary for opinions of
counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred
to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”))
of the Backstop Investor who agrees to sell or otherwise transfer the Securities only in accordance with this Section 3.5 and
who is an Accredited Investor, (d) the Securities are sold pursuant to Rule 144, and the Backstop Investor shall have delivered
to the Company an opinion of counsel as set forth in clause (b) or (e) the Securities are sold pursuant to Regulation S under
the 1933 Act (or a successor rule) (“Regulation S”), and the Backstop Investor shall have delivered to the Company
an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions
to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from registration
under the 1933 Act, which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule
144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such
Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and
regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register the
Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder.
Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in
connection with a bona fide margin account or other lending arrangement.

 

3.6 
Legends. The Backstop Investor understands that the Backstop Warrant and Backstop Shares have been registered under
the 1933 Act or otherwise may be sold pursuant to Rule 144, the Backstop Warrant and Backstop Shares may bear a restrictive legend
in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED
OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY
SHALL HAVE RECEIVED AN OPINION OF COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS
OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED UNDER SUCH ACT, THE SUBSTANCE OF WHICH OPINION SHALL BE REASONABLY ACCEPTABLE
TO THE COMPANY.”

 

    	 	3	 

     

    

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Securities
upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Securities are registered
for sale under an effective registration statement filed under the 1933 Act, or (b) such holder provides the Company with an opinion
of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public
sale or transfer of such Securities may be made without registration under the 1933 Act, which opinion shall be accepted by the
Company so that the sale or transfer is effected or (c) such holder provides the Company with reasonable assurances that such
Securities can be sold pursuant to Rule 144 or Regulation S and a legal opinion to support such assurances. The Investor agrees
to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance
with applicable prospectus delivery requirements, if any.

 

3.7 
Authorization; Enforcement. This Agreement and the other Transaction Documents have each been duly and validly authorized
by the Backstop Investor. This Agreement has been duly executed and delivered on behalf of the Backstop Investor, and constitute
valid and binding agreements of the Backstop Investor, enforceable against the Investor in accordance with their terms.

 

3.8 
Residency. The Backstop Investor is a resident of the jurisdiction set forth immediately below the Backstop Investor’s
name on Exhibit 1 hereto.

 

4. MISCELLANEOUS.

 

4.1 
Notices. Any notices required or permitted to be given under the terms of this Agreement shall be sent by certified
or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery
service) or by facsimile and shall be effective five days after being placed in the mail, if mailed by regular United States mail,
or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, in
each case addressed to a party. The addresses for such communications shall be:

 

	If
    to the Company, to:	Adial
        Pharmaceuticals, Inc.

        1180 Seminole Trail

        Charlottesville, Virginia 22901

        Attention: William B. Stilley

        Telephone: (434) 422-9800

        Facsimile: 

         

	With
    a copy to:	Gracin
    & Marlow, LLP

    The Chrysler Building

    405 Lexington Avenue, 26th Floor

    New York, New York 10174

    Facsimile No.: (212) 208-4657

    Attention: Leslie Marlow, Esq.

    E-mail: lmarlow@gracinmarlow.com

 

    	 	4	 

     

    

 

If
to the Backstop Investor, to the address set forth on the signature page. Each party shall provide notice to the other party of
any change in address.

 

4.2 
Headings. The section and subsection headings in this Agreement are inserted for convenience only and shall not affect
in any way the meaning or interpretation of this Agreement.

 

4.3 
Construction. The parties hereto and their respective legal counsel participated in the preparation of this Agreement,
and therefore, this Agreement shall be construed neither against nor in favor of any of the parties hereto, but rather in accordance
with the fair meaning thereof.

 

4.4 
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any
Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced,
the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated
to the greatest extent possible.

 

4.5 
Entire Agreement. This Agreement and the agreements and documents referenced herein constitute the entire agreement of
the parties hereto with respect to the subject matter hereof and supersede all prior agreements and undertakings, both written
and oral, among the parties hereto with respect to the subject matter hereof.

 

4.6 
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Except as set forth below, neither this Agreement nor any of the rights, interests or obligations
under this Agreement will be assigned by any party (whether by operation of law or otherwise) without the prior written consent
of the other parties.

 

4.7 
No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the parties hereto
and their respective successors and permitted assigns and, except as expressly set forth in Section 4.6, nothing herein,
express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any
nature whatsoever, including any rights of employment for any specified period, under or by reason of this Agreement.

 

4.8 
Governing Law. This Agreement shall be interpreted, construed and enforced in accordance with the laws of the State of
New York, without regard to the conflicts of law principles thereof.

 

    	 	5	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

 

	MVA
                                         151 Investors LLC

	 	Adial
                                         Pharmaceuticals, Inc.

	 	 	 	 	 
	Signed:	/s/
    Kevin Schuyler	 	Signed:	/s/
    William Stilley
	 	Kevin
    Schuyler	 	 	William
    Stilley
	 	Managing
    Member	 	 	CEO
	 	 	 	 	 
	Address:	 

                                                                                                            

        MVA
        151 Investors LLC

        c/o
        Kevin Schuyler

        2521
        Summit Ridge Trail

        Charlottesville,
        VA 22911
	 	 	 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]